Expert Consensus on the Clinical Management of Melasma: A Delphi Method Study

December 20, 2025 updated by: Venus Research Center
This study aims to gather expert opinions on the best ways to treat and manage melasma, a common skin condition characterized by dark patches on the face. Using a method called the Delphi Method, a group of dermatologists and other specialists will participate in several rounds of surveys to share their insights and reach a consensus on the most effective treatments and management strategies. The goal is to create a set of evidence-based guidelines that can help doctors provide more consistent, effective care for patients with melasma. The study will ensure that all experts' opinions are anonymous, and the results will be shared to improve treatment practices worldwide.

Study Overview

Status

Enrolling by invitation

Detailed Description

This study is designed to establish expert consensus on the management and treatment of melasma through a Delphi Method approach. The Delphi Method is a structured, iterative process where a panel of specialists-primarily dermatologists and other healthcare professionals experienced in treating melasma-will be asked to respond to a series of surveys. These surveys will allow experts to share their opinions on the most effective treatments, diagnostic criteria, and management strategies for melasma.

The study will be conducted in multiple rounds:

Round 1: Experts will provide open-ended feedback on their experiences and perspectives on melasma treatment.

Round 2: Based on the responses from Round 1, a refined set of questions will be circulated to clarify or expand on the issues raised.

Round 3: A final round will help refine and solidify the consensus on treatment approaches and care protocols.

The experts' feedback will be anonymized to ensure unbiased responses, and each round will be followed by analysis to identify areas of agreement and disagreement. The goal is to achieve a high level of consensus (usually around 70%) on key treatment recommendations and best practices for managing melasma.

This process will result in evidence-based guidelines for melasma treatment that healthcare providers can use to standardize care and improve patient outcomes. These guidelines will help address the variability in treatment practices and ensure that patients receive the most effective and up-to-date care based on expert consensus.

Study Type

Observational

Enrollment (Estimated)

15

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cairo, Egypt
        • Venus Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Target population:A purposive sample of experienced clinical dermatologists who actively manage melasma. The panel will include clinicians with diverse practice settings and geographic representation relevant to the study scope.Panel size and rationale:Target enrolment: 20-35 experts.Rationale: this size balances breadth of opinion and feasibility for iterative Delphi rounds; it is large enough to capture diverse viewpoints yet small enough to allow meaningful, anonymized feedback and analysis.Minimum required for analysis: 15 panelists

Description

Inclusion Criteria:

  • Board-certified or equivalent dermatologist,
  • Minimum of 5 years of post-certification clinical experience in the management of MELASMA,
  • Willingness to participate in all Delphi rounds.

Exclusion Criteria:

  • Inability or unwillingness to complete Delphi rounds.
  • Lack of clinical experience with MELASMA
  • Industry representatives without direct clinical practice

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Expert Panel
A cohort of dermatology and aesthetic medicine experts participating in a Modified Delphi process to develop consensus recommendations on the management of melasma

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Consensus on Diagnostic & therapeutic Criteria for Melasma
Time Frame: 6-12 weeks
Establishment of expert consensus on core domains of melasma diagnosis and management measured by the proportion of statements reaching predefined consensus agreement after completion of delphi rounds
6-12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

December 30, 2026

Study Registration Dates

First Submitted

December 8, 2025

First Submitted That Met QC Criteria

December 8, 2025

First Posted (Estimated)

December 22, 2025

Study Record Updates

Last Update Posted (Actual)

December 29, 2025

Last Update Submitted That Met QC Criteria

December 20, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Delphi studies do not collect patient data, medical records, biological samples, or identifiable clinical information. Experts only give opinions, not "IPD." Their responses are anonymized, and sharing identifiable expert-level responses is not required and often discouraged

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Melasma

Subscribe